1. SUMMIT OUTLINES CLINICAL DEVELOPMENT PLANS FOR UTROPHIN MODULATOR PROGRAMME FOR DUCHENNE MUSCULAR DYSTROPHY

    Posted on March 21, 20132:03 pm

    • First patient clinical trials of SMT C1100 expected to start H2 2013 •Summit to showcase programme at international scientific conference Oxford, UK, 21 March 2013 – Summit (AIM: SUMM), a drug discovery and development company advancing therapies for Duchenne Muscular Dystrophy (‘DMD’) and C. difficile infections, today outlines its future plans for the continued Read more »

  2. Drisapersen/GSK Update

    Posted on March 4, 20134:55 pm

    Dear Debra, Since my last email you may have seen a recent story that appeared on an investment tips website regarding a presentation on drisapersen made at the Duchenne Parent Project Onlus meeting on 24th February 2013 in Rome, Italy. We appreciate that the story may raise questions for you, so I wanted to write and Read more »